These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 25990613)

  • 1. Commentary on: "Satisfaction with information used to choose prostate cancer treatment." Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Urology, Emory University, Atlanta, Georgia; Department of Urology, University of Michigan, Ann Arbor, Michigan; Department of Psychiatry and Public Health Institute, University of California-San Francisco, California; Institute for Public Policy and Social Research, Michigan State University, Lansing, Michigan; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio; Department of Urology and Department of Health Policy and Management, University of California-Los Angeles, Los Angeles, California; Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.: J Urol 2014;191(5):1265-71. doi:10.1016/j.juro.2013.12.008. [Epub 2013 Dec 12].
    Brent H
    Urol Oncol; 2016 May; 34(5):247-8. PubMed ID: 25990613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satisfaction with information used to choose prostate cancer treatment.
    Gilbert SM; Sanda MG; Dunn RL; Greenfield TK; Hembroff L; Klein E; Saigal CS; Pisters L; Michalski J; Sandler HM; Litwin MS; Wei JT
    J Urol; 2014 May; 191(5):1265-71. PubMed ID: 24333514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Johns Hopkins University, Baltimore; University of Wisconsin Carbone Cancer Center; School of Medicine and Public Health; Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Mayo Clinic, Rochester, MN; University Hospitals Case Medical Center, Seidman Cancer Center; Cleveland Clinic Taussig Cancer Institute; Both in Cleveland; University of Virginia Cancer Center, Charlottesville; Comprehensive Cancer Centers of Nevada, Las Vegas; Siteman Cancer Center, Washington University School of Medicine, St. Louis; NorthShore University Health System, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor; Rutgers Cancer Institute of New Jersey, New Brunswick.N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747.
    Scott E
    Urol Oncol; 2017 Mar; 35(3):123. PubMed ID: 28159490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on "factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE)." Resnick MJ, Guzzo TJ, Cowan JE, Knight SJ, Carroll PR, Penson DF, VA Tennessee Valley Geriatric Research, Education and Clinical Care, Nashville, TN.: BJU Int 2013;111(2):213-20. [Epub 2012 Aug 29]. doi: 10.1111/j.1464-410X.2012.11423.x.
    Hollenbeck BK
    Urol Oncol; 2014 Oct; 32(7):1090. PubMed ID: 25443145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
    Trump D
    Urol Oncol; 2016 May; 34(5):249-50. PubMed ID: 25907621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database.
    Lai MW; Klein-Schwartz W; Rodgers GC; Abrams JY; Haber DA; Bronstein AC; Wruk KM
    Clin Toxicol (Phila); 2006; 44(6-7):803-932. PubMed ID: 17015284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.
    Jayadevappa R; Chhatre S; Whittington R; Bloom BS; Wein AJ; Malkowicz SB
    BJU Int; 2006 May; 97(5):955-62. PubMed ID: 16643477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancer.
    Naitoh J; Witte O; Belldegrun A
    Cancer Res; 1998 Jul; 58(13):2895-900. PubMed ID: 9661908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University of Michigan, Ann Arbor, MI.: J Urol 2012;188(6):2114-9. [Epub 2012 Oct 18]. doi: 10.1016/j.juro.2012.08.005.
    Hollenbeck BK
    Urol Oncol; 2014 Oct; 32(7):1089. PubMed ID: 25443143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regret in men treated for localized prostate cancer.
    Hu JC; Kwan L; Saigal CS; Litwin MS
    J Urol; 2003 Jun; 169(6):2279-83. PubMed ID: 12771770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mack Roach III, MD, expert radiation oncologist and prostate cancer specialist, par excellence!
    Dawson G
    J Natl Med Assoc; 2009 Nov; 101(11):1180-2. PubMed ID: 19998649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on "Abiraterone in metastatic prostate cancer without previous chemotherapy." Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. N Engl J Med 2013;368(2):138-48 [Epub 2012 Dec 10]; N Engl J Med 2013;368(6):584.
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1846. PubMed ID: 24210085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary on "Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer." Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Harvard Radiation Oncology Program, Boston, MA.: Cancer 2013;119(9):1729-35. doi: 10.1002/cncr.27956. [Epub 2013 Feb 22].
    Gottschalk A
    Urol Oncol; 2014 Apr; 32(3):373-4. PubMed ID: 24679463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nurse practitioner in family planning services: law and practice.
    Roemer R
    Fam Plann Popul Rep; 1977 Jun; 6(3):28-34. PubMed ID: 12259979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary on: "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study." Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be. Aarhus University Hospital, Aarhus, Denmark. Herlev Hospital, Herlev, Denmark. AZ Groeninge Kortrijk, Kortrijk, Belgium. UZ Leuven, Leuven, Belgium. Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. UZ Brussel, Brussels, Belgium. Univerzita Karlova v Praze, Prague, Czech Republic. Astellas Pharma Global Development, Leiden, Netherlands. Astellas Pharma Global Development, Northbrook, IL, USA. Medivation Inc, San Francisco, CA, USA. Massachusetts General Hospital Cancer Center, Boston, MA, USA: Lancet Oncol. 2014 May;15(6):592-600; doi: 10.1016/S1470-2045(14)70129-9. [Epub 2014 Apr 14].
    Trump D
    Urol Oncol; 2016 May; 34(5):248-9. PubMed ID: 25937426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. J. Stephen Jones, M.D., F.A.C.S., is Chairman of the Department of Regional Urology at the Cleveland Clinic Glickman Urological and Kidney Institute.
    Urology; 2008 Nov; 72(5):959. PubMed ID: 18984131
    [No Abstract]   [Full Text] [Related]  

  • 17. Commentary on "Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare." Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY. J Urol 2013; 189(3):867-70. [Epub 2012 Oct 9]. doi: 10.1016/j.juro.2012.10.005.
    Eggener S
    Urol Oncol; 2014 Aug; 32(6):935-6. PubMed ID: 25087672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on "Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy." Lee JY, Diaz RR, Cho KS, Lim MS, Chung JS, Kim WT, Ham WS, Choi YD, Department of Urology, Yonsei University College of Medicine, Seoul, Republic of Korea; Severance Hospital and Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.: J Urol 2013; 190(4):1192-9. doi:10.1016/j.juro.2013.04.077. [Epub 2013 May 3].
    Kamat A
    Urol Oncol; 2015 Jan; 33(1):46. PubMed ID: 25528637
    [No Abstract]   [Full Text] [Related]  

  • 19. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.
    Stewart SB; Bañez LL; Robertson CN; Freedland SJ; Polascik TJ; Xie D; Koontz BF; Vujaskovic Z; Lee WR; Armstrong AJ; Febbo PG; George DJ; Moul JW
    J Urol; 2012 Jan; 187(1):103-8. PubMed ID: 22088334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary and alternative medicine use among newly diagnosed prostate cancer patients.
    McDermott CL; Blough DK; Fedorenko CR; Arora NK; Zeliadt SB; Fairweather ME; Oakley-Girvan I; Van Den Eeden SK; Ramsey SD
    Support Care Cancer; 2012 Jan; 20(1):65-73. PubMed ID: 21120540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.